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Abstract 
Systems Biology approach involves integration of experimental and computational research to 
understand complex biological systems. Alexander's Disease (AxD) was first described by W. S. 
Alexander in 1949, and is a rare, but often fatal neurological disorder that has been divided into three 
subtypes based on the age of onset: the infantile, juvenile and adult forms that are shown to be caused 
by mutations in the gfap gene. The infantile form, with onset between birth and about two years of age, is 
currently the most common form of the disease. The characteristic neuropathological feature of all forms 
of AxD is the presence of Rosenthal fibers. In present study, the mutant GFAP protein associated with 
AxD was investigated by predicting the structure of wild type and mutant GFAP protein. It was found that 
due to the reported single point mutation, even though both the wt and mutant GFAP proteins adopt a 
right handed alpha helix structure but large number of residues in the mutant GFAP were spread in the 
region of left-handed helix and beta sheets in the Ramachandran Plots. This resulted in a large 
conformational change which may be responsible for the cause of aggregation of mutant GFAP forming 
Rosenthal Fibers. In the absence of any commercially available drug to alleviate the symptoms of AxD, 
the therapeutic intervention of mutant GFAP protein was done using structure based drug design 
approach. The drug dibutyryl cyclic AMP identified through data mining from STITCH 4.0 was found to be 
toxic and therefore its structural analogs were generated using GAUSSIAN 09. Each of the 20 structural 
analogs of dbcAMP were docked with mutant GFAP using Discovery Studio 2.5 and analyzed for their 
toxicity potential using OSIRIS Property Explorer. Two structural analogs i.e. DBCM17 and DBCM20 
were found to have favorable docking, druglikeness and did not pose any toxicity risk. These structural 
analogs identified may be further analyzed for therapeutic intervention of AxD by their role in prevention 
of aggregation of mutant GFAP. 
Keywords: In Silico; Structure Based Drug Design; Alexander Disease; Point Mutation; Rosenthal 
Fibers.
 
1. Introduction 
Computational biology, through pragmatic modeling and theoretical exploration, provides a powerful foundation to 
formulate and solve critical biological problems [1]. Alexander disease (AxD), also known as fibrinoid 
leukodystrophy, is a progressive and fatal neurodegenerative disease that affects the midbrain and cerebellum of the 
central nervous system. It is a rare genetic disorder that mostly affects infants and children, causing developmental 
delay and changes in physical characteristics. The destruction of white matter in the brain is accompanied by the 
formation of fibrous, eosinophilic deposits known as Rosenthal fibers [2]. Rosenthal fibers appear not to be present 
in healthy people, but occur in specific diseases, like some forms of cancer. They are aggregations of protein that 
occurs in astrocytes, which are supporting cells of the brain. These aggregates are found in other disorders, but not 
with the abundance of particular distribution in the brain that occurs in AxD.  Mutations in the coding region of 
gfap that codes for glial fibrillary acidic protein (GFAP) which maps to chromosome 17q21 [3] and have been 
shown to contribute to the accumulation of Rosenthal fibers [4]. Most of the gfap mutations that have been 
identified in AxD are heterozygous, sporadic and missense mutations as reported by Nam et al. (2015). 
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Analysis of the proband’s gfap revealed a heterozygous G to T substitution in exon 6 at position 934, causing an 
amino acid change at codon 312, a G to T change converts a glutamate GAG codon to a TAG nonsense codon, 
resulting in deletion of 121 amino acids [5]. Like other intermediate filament proteins, GFAP consists of a central 
four-part alpha helical rod segment flanked by N-terminal head and C-terminal tail random coils. The mutation 
leads to the deletion of rod domain and whole tail domain in the GFAP. The tail domain is critical to the proper 
assembly of GFAP, the mutated gfap could not form proper GFAP networks, thereby leading to the formation of 
aggregates [6]. 
The current standard of treatment for AxD is symptomatic and focuses on major problems such as seizure control, 
nutrition, and maintenance of pulmonary function. Only three reports describe attempts at alternative forms of 
therapy. One patient, studied prior to the discovery of gfap mutations as the cause of the disease, was given bone 
marrow transplantation based on the mistaken analogy to other leukodystrophies that are treated in such a manner 
that the patient died 4.5 months after transplantation, at the age of 1 year [7]. 
Therefore in the absence of any therapy/ commercially available drug for treatment of AxD or alleviation of its 
neuropathological feature of aggregation of Rosenthal Fibers, the present study was undertaken. The aim of the 
present work is to predict the structure of wt GFAP protein, its mutant and to further develop a potential therapeutic 
agent which may prevent the aggregation of mutant GFAP protein. 
2. Methodology 
2.1. Structure Modeling 
The GFAP protein sequence of Homo sapiens was retrieved from UniProt with ID P14136. The structure of glial 
fibrillary acidic protein (humans) was not available in PDB therefore it was predicted using I-TASSER which is an 
integrated platform for automated protein structure and function prediction based on the sequence-to-structure-to-
function paradigm [8]. 
Verify3D was used for quality assessment of the structure. It determines the compatibility of an atomic model (3D) 
with its own amino acid sequence (1D) by assigning a structural class based on its location and environment (alpha, 
beta, loop, polar, nonpolar etc.) and comparing the results to valid structures. The vertical axis in the plot represents 
the average 3D-1D profile score for each residues in a 21-residue sliding window and the scores ranges from -1 
(bad score) to +1 (good score) [9]. 
Also, Ramachandran Plot was constructed using Swiss-PDB Viewer to check the allowed and disallowed regions of 
torsion angle values, serving as an important indicator of the quality of protein three-dimensional structures torsion 
angle values [10]. 
2.2. Structure Based Drug Design 
No commercially available drug has been reported for treatment of AxD therefore, STITCH 4.0 was used to identify 
the ligands for Homo sapiens GFAP and their structure was obtained from PubChem. 
Osiris Property Explorer and Toxicity Checker was used to check the toxicity risk assessment and other parameters 
such as the drug score which combines druglikeness, cLogP, logS, molecular weight and toxicity risks in one handy 
value than may be used to judge the compound's overall potential to qualify for a drug [11]. 
Structural analogs were generated in GaussView module available in GAUSSIAN 09. The GaussView has 
the Clean menu which adjust the geometry of the drawn molecule, based on a defined set of rules, to more closely 
match chemical intuition and thus making respective structure stable [12]. 
Docking was performed using LigandFit module of Discovery Studio 2.5. The method employs a cavity detection 
algorithm for detecting invaginations in the protein as candidate active site regions. Candidate poses are minimized 
in the context of the active site using a grid-based method for evaluating protein-ligand interaction energies. Errors 
arising from grid interpolation are dramatically reduced using a new non-linear interpolation scheme [13]. 
3. Results 
Alexander Disease (AxD) is caused by mutations in gfap that encodes a type III intermediate filament 
predominantly found in astrocytes within the CNS.  AxD is caused by the heterozygous mutations in the gene for 
glial fibrillary acidic protein, due to which prominent protein aggregates inside astrocytes are formed. Loss of 
myelin and oligodendrocytes is also observed along with neuronal degeneration [14]. 
3.1. Structure Modeling 
Structure of wild type GFAP protein or mutated GFAP resulting from deletion of 121 amino acids [10] was not 
available in the protein structure database. Therefore, to predict the structure of wild type and mutant protein the 
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sequence of GFAP of Homo sapiens was retrieved from UniProt having ID P14136 in the FASTA format. The 
sequence of mutated protein was obtained by removing 121 residues from the C- terminal of the wt protein which 
corresponds to mutation at 312 codon reported by Nam et al. (2015) [5]. 
The 3D structure of wild-type GFAP and mutant type was predicted using I-TASSER which is top ranked in 
CASP7 to CASP11 [15]. I-TASSER model with the highest confidence scores for wt GFAP and mutant GFAP were 
selected for further analysis (figure 1A and 1B). 
 
 
 
Figure 1: The structure of (A, C) wild type GFAP (432 residues) and (B, D) mutated GFAP (312 residues) 
predicted by I-TASSER and their corresponding Ramachandran Plots 
On analysis of the Ramachandran Plot of wt GFAP and mutant GFAP, it was observed that the wt protein adopts a 
right handed alpha helix structure. But the residues in the mutant GFAP were also spread in the region of left-
handed helix and beta sheets resulting in change of structure and distortion of the protein due to deletion of 121 
amino acid residues following the point mutation in the gene at codon 312 as compared to the wt GFAP as can be 
seen from figure 1. The secondary structure element of α-helix is a common structural feature of proteins forming 
plaques in other neurogical diseases such as Parkinson's Disease, Huntington's Disease [16] and Prion Disease [17] 
as also in mutant GFAP protein of AxD. The distortion of mutant GFAP in comparison to the wt is also observed on 
superimposition of the two structures with an RMSD of 1.375Å. 
From the results of Verify3D it was observed that in the wt-GFAP graph residue number 1-70, 90-130, 170-185, 
230-290 and 300-400 are well predicted as they have score near to +1 (shown in figure 2A) and there are few 
residues that have not predicted reliably such as 70-90, 130-170, 185-230, 290-300 and  400-420 having score less 
than zero. On the other hand, in the mutant GFAP graph the residue numbers 20-120, 180-255, 270-290 were 
conjectured well having score greater or equal to 1 whereas residue number such as 1-20, 120-180, 260-270 and 
290-300 were not reliably predicted (shown in figure 2B). 
 
 
A B 
C D 
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Figure 2: Verify3D validation of (A) wild-type GFAP and (B) mutant GFAP 
3.2. Structure based drug design 
In the absence of any commercially available drug reported for GFAP. The ligands for Homo sapiens GFAP were 
retrieved using STITCH 4.0 and the chemical compound dibutyryl cyclic AMP was found to be interacting with 
GFAP (Figure 3). 
 
Figure 3: Ligand retrieved for GFAP using STITCH 4.0. 
The drug dibutyryl cAMP (CID: 2460) has been reported to be used for the treatment of hepatocellular carcinoma 
[18]. Its structure and SMILES representation were retrieved from PubChem. 
 
 
On investigation of dibutyryl cAMP for its toxicity risk using OSIRIS Property Explorer it was found to have 
unknown chirality and no results were obtained and therefore was further checked with Toxicity Checker and it was 
found to be toxic. Due to the toxic nature of dbcAMP it cannot be further investigated for its potential as a 
therapeutic agent. Therefore, twenty structural analogs were constructed in Gaussian 09 software by modification of 
dbcAMP. 
All the 20 compounds were checked for their toxicity risks using OSIRIS Property Explorer and were docked with 
mutant GFAP using Discovery Studio 2.5 (Table 1). None of the analogs showed any toxicity risk analyzed in terms 
of mutagenecity, tumorogencity, irritability and reproductive effects. Out of the 20 analogs it was found that the 
compounds DBCM12, DBCM17 and DBCM20 (figure 4) had docking scores greater than dbcAMP docked with 
mutant GFAP and also greater than the scores of other variants (Table 1). The docking of dbcAMP and analog 
DBCM20 with mutant GFAP and its corresponding binding residue are shown in figure 5. From table 2 it was 
observed that amino acid residues LEU90 GLU91, ASN94, LEU193, ILE197, HIS251, GLU254, and GLU255 
A B 
PubChem CID: 2460 
CCCC(=O)NC1=NC=NC2=C1N=C
N2C3C(C4C(O3)COP(=O)(O4)O)O
C(=O)CCC  
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were common in the binding pocket of mutant GFAP and were surrounding the ligands namely DBCM12, 
DBCM17 and DBCM20 respectively. 
Even though DBCM12 had the highest dock score, its druglikeness was negative and it possessed the lowest drug 
score (OSIRIS Property Explorer) thereby making it unsuitable as a potential drug. Therefore, the analog DBCM20 
having a high druglikeness and dock score (Discovery Studio 2.5) followed by DBCM17 are potential therapeutic 
agents. These may be further investigated for their therapeutic potential to treat AxD by prevention of aggregation 
of Rosenthal Fibers. 
 
 
Figure 4: Structure of (A) DBCM12 and (B) DBCM20 
Table1: Docking scores, toxicity risk and drug-likeness parameters of dibutyryl cAMP (dbcAMP) and 
its structural analogs 
Variants Dock score TR
* 
cLogP logS M.W. TPSA DL
* 
Drug Score 
dbcAMP 54.41 Yes - - - - - - 
DBCM1 30.28 No 1.08 -2.74 219 72.7 -2.03 0.52 
DBCM2 33.33 No 1.22 -0.88 240 59.81 0.69 0.8 
DBCM3 34.19 No 1.27 -3.24 237 98 -0.33 0.54 
DBCM4 30.27 No 1.03 -0.9 236 93.95 -1.15 0.6 
DBCM5 34.65 No 1.66 2.49 262 59.81 -0.09 0.71 
DBCM6 36.12 No 1.47 0.07 351 72.7 2.07 0.86 
DBCM7 37.14 No 1.47 0.07 307 72.7 2.07 0.89 
DBCM8 33.70 No 1.1 -2.71 235 92.93 0.7 0.77 
DBCM9 40.35 No 2 -2.93 262 80.04 1.71 0.83 
DBCM10 43.95 No 2.35 -3.69 325 81.93 -0.94 0.52 
DBCM11 48.94 No 2.95 -4.43 359 81.93 -1.24 0.44 
DBCM12 99.51 No 2.39 -4.22 364 97.72 -0.98 0.48 
DBCM13 38.03 No 0.87 -1.22 267 89.77 2.8 0.93 
DBCM14 49.89 No 3.19 -4.93 381 110.1 -0.65 0.43 
DBCM15 52.17 No 1.64 -4.16 384 122.2 0.13 0.58 
DBCM16 54.28 No 3.12 -4.41 456 93.96 0.09 0.48 
DBCM17 56.02 No 2.89 -4.28 456 93.96 0.49 0.52 
DBCM18 55.59 No 3.35 -4.55 422 93.96 -3.08 0.33 
DBCM19 50.05 No 2.12 -3.51 435 117.8 0.19 0.58 
DBCM20 59.60 No 1.74 -4.22 437 123.0 1.04 0.60 
TR
*
- Toxicity Risks;  DL
*
- Druglikeness 
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Figure 5: Docking and binding site residues of mutant GFAP with (A, C) dbcAMP and (B, D) DBCM20 
Binding site residues of GFAP with dbcAMP. 
 
Table 2: Binding pocket residues interacting with dbcAMP and analogs 
Compound Binding pocket residues No. of H-
bonds 
Residues exposed to 
solvent 
dbcAMP VAL87, LEU90, GLU91, 
ASN94, LEU193, ILE197, 
ILE190, LEU200, MET245, 
ALA246, SER247,  SER248, 
ASN249, MET250, HIS251,   
ALA253, GLU254, GLU255 
and  ARG258 
2 (HIS251 and 
GLU254) 
LEU90, ASN94, LEU193, 
HIS251, and GLU254 
DBCM12 VAL87, LEU90, GLU91, 
ASN94, LYS95,  LEU193, 
ILE197, LEU200, MET250, 
HIS251, ALA253, GLU254, 
GLU255 and TYR257 
1 (GLU255) VAL87, LEU90, GLU91, 
ASN94, LYS95,  LEU193, 
ILE197, MET250, 
HIS251, GLU254, 
GLU255 and TYR257 
DBCM17 LEU90, GLU91, ASN94, 
LYS95, LEU193, ILE197, 
HIS251, GLU254, GLU255 
and TYR257 
1 (ASN94) LEU90, GLU91, LYS95, 
ASN94, LEU193, ILE197,  
HIS251, GLU254 and 
GLU255 
DBCM20 VAL87, ARG88, LEU90, 
GLU91, ASN94, LYS95, 
ILE190, LEU193, ILE197, 
MET250, HIS251,GLU254, 
ALA253, GLU255, TRP256 
and TYR257 
3 (ASN94, 
GLU254 and 
GLU255) 
VAL87, ARG88, LEU90, 
GLU91, ASN94, LYS95, 
ILE197, HIS251, 
MET250, GLU254, and 
GLU255 
 
A B 
C D 
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4. Conclusion 
Based on the docking results it can be concluded that the drug obtained through data mining from STITCH 4.0 
dibutyryl cAMP (dbcAMP) cannot be used therapeutically due to its high toxicity. Therefore 20 structural analogs 
were generated and analyzed using in silico tools. The structural analogs DBCM17 and DBCM20 were found to 
have favorable docking scores, druglikeness and did not pose any toxicity risk. These compounds may further be 
investigated for their efficacy for treatment of Alexander Disease to alleviate the symptoms associated with AxD 
and prevent aggregation of mutant GFAP that form Rosenthal Fibers. 
5. List of Abbreviations 
AxD: Alexander Disease, GFAP: Glial fibrillary acidic protein, dbcAMP: dibutyryl cyclic adenosine 
monophosphate, TR: Toxicity Risks, DL: Druglikeness. 
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